Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2016-10-03Clinical Trial Update: A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy [Phase 2]
Phase 2 proof-of-concept study investigating maintenance tasquinimod in metastatic castration-resistant prostate cancer patients non-progres…
-
CLINICAL_TRIALS trial_result · 2016-09-29Clinical Trial Update: Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases [Phase 1, Phase 2]
This Phase 1/2 trial update assesses the safety of re-treatment with Radium-223 dichloride in men with metastatic castration-resistant prost…
-
FDA approval · 2016-09-12FDA Approved: JEVTANA — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for JEVTANA (cabazitaxel) from Sanofi-Aventis U.S. LLC.
-
CLINICAL_TRIALS withdrawal · 2016-08-31Clinical Trial Update: Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With Hormone Resistant Metastatic Prostate Cancer [NA]
The clinical trial using PET tracers carbon-11 acetate and fluorine-18 sodium fluoride to assess treatment response in hormone-resistant met…
-
CLINICAL_TRIALS withdrawal · 2016-08-17Clinical Trial Update: Cabazitaxel in mCRPC Patients With AR-V7 Positive CTCs [Phase 2]
A Phase 2 trial evaluating cabazitaxel in metastatic castration-resistant prostate cancer patients with AR-V7 positive circulating tumor cel…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2016-08-12Clinical Trial Update: A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030) [Phase 3]
A Phase 3 trial evaluating MK0822 for prolonging time to first bone metastasis in men with castration-resistant prostate cancer has been wit…
-
CLINICAL_TRIALS trial_result · 2016-07-26Clinical Trial Update: Study to Determine the Feasibility, Evaluability and Variability in Markers of Drug Action in Castration Resistant Prostate Cancer
Completed clinical trial evaluating feasibility, evaluability, and variability in markers of drug action in metastatic castration-resistant …
-
CLINICAL_TRIALS trial_result · 2016-07-06Clinical Trial Update: Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer [Phase 4]
Phase 4 trial completion update for cabazitaxel combined with prednisone and neutropenia-prophylaxis in metastatic castration-resistant pros…
-
CLINICAL_TRIALS trial_result · 2016-06-30Clinical Trial Update: A Phase IIb Study to Evaluate Efficacy and Tolerability of ODX (Osteodex) in Metastatic CRPC [Phase 2]
DexTech Medical AB's Phase IIb study of ODX (Osteodex) in metastatic castration-resistant prostate cancer has been terminated.
-
CLINICAL_TRIALS withdrawal · 2016-06-10Clinical Trial Update: TAK-700 in Castration Resistant Prostate Cancer [Phase 2]
A Phase 2 trial of TAK-700 (orteronel) for castration-resistant prostate cancer has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2016-06-02Clinical Trial Update: Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer [Phase 4]
This Phase 4 trial update assesses the safety of cabazitaxel (Jevtana) in patients with metastatic castration-resistant prostate cancer. The…
-
CLINICAL_TRIALS trial_result · 2016-06-01Clinical Trial Update: Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 2]
Phase 2 study evaluating the impact of Orteronel on QT/QTc interval in patients with metastatic castration-resistant prostate cancer; result…
-
FDA label_change · 2016-05-27FDA Approved: JEVTANA — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for JEVTANA (cabazitaxel) submitted by Sanofi-Aventis U.S. LLC.
-
FDA approval · 2016-05-17FDA Approved: ZYTIGA — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for ZYTIGA (abiraterone acetate) submitted by Janssen Biotech, expanding its labeling.
-
FDA approval · 2016-05-12FDA Approved: XOFIGO — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for XOFIGO (radium-223 dichloride) submitted by Bayer HealthCare Pharmaceuticals Inc.
-
CLINICAL_TRIALS trial_result · 2016-05-09Clinical Trial Update: A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer [NA]
Pilot study results for a combination of parenteral testosterone and oral etoposide in men with castration-resistant prostate cancer; the tr…
-
CLINICAL_TRIALS trial_result · 2016-05-02Clinical Trial Update: Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone [Phase 2]
A Phase 2 trial of cabozantinib in metastatic castration-resistant prostate cancer with bone metastases was terminated, and results have bee…
-
FDA approval · 2016-04-29FDA Approved: XOFIGO — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for XOFIGO (radium Ra-223 dichloride) submitted by Bayer HealthCare Pharmaceuticals Inc.
-
CLINICAL_TRIALS trial_result · 2016-04-28Clinical Trial Update: F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer [Phase 2, Phase 3]
The Phase 2/3 clinical trial evaluating F-choline PET for early response assessment in castration-resistant prostate cancer has been termina…
-
CLINICAL_TRIALS trial_result · 2016-04-15Clinical Trial Update: A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 2]
This document reports the completion of a Phase 2 trial evaluating BIND-014, a docetaxel nanoparticle formulation, in patients with metastat…
-
CLINICAL_TRIALS trial_result · 2016-04-15Clinical Trial Update: A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies [Phase 1]
Phase 1 study of nivolumab (BMS-936558) in advanced or recurrent malignancies completed; results posted.
-
CLINICAL_TRIALS trial_result · 2016-03-25Clinical Trial Update: An Open Trial to Assess the Efficacy and Safety of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer [Phase 2]
This document reports the completion results of an open Phase 2 trial evaluating the efficacy and safety of oral thalidomide in patients wit…
-
FDA approval · 2016-03-18FDA Approved: XOFIGO — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for XOFIGO (radium-223 dichloride) from Bayer HealthCare Pharmaceuticals Inc.
-
CLINICAL_TRIALS trial_result · 2016-02-25Clinical Trial Update: A Pilot Study of Exercise in Patients With Docetaxel-Based Chemotherapy for Hormone Refractory Prostate Cancer [Phase 2]
Phase 2 pilot study evaluating an exercise program in patients with metastatic castration-resistant prostate cancer undergoing docetaxel-bas…
-
CLINICAL_TRIALS trial_result · 2016-02-12Clinical Trial Update: Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC) [Phase 2]
Phase 2 clinical trial evaluating the combination of thalidomide and Doxil in patients with androgen-independent prostate cancer; results ha…